The global tumor necrosis factor inhibitor drugs market size
is anticipated to reach USD 42.1 billion by 2026, according to a report published
by Grand View Research, Inc. Increasing prevalence of autoimmune diseases,
rapid technological advancements, and rise in healthcare expenditure across the
globe are some of the major factors expected to drive the growth.
Currently, there are five
approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel
(etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and
Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have
been launched, causing a significant paradigm shift in the market.
The wave of biosimilars
pose a significant internal threat to the biologics sale as biosimilars have a
comparable efficiency as the original products. The cost-effectiveness of
biosimilars makes them an attractive choice in economically sensitive areas. In
addition, emerging countries, such as India, China, and South Korea are active
participants in the biosimilar market.
Some of the key
therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid
arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative
colitis. Although these medicines are mostly used for the treatment of
autoimmune diseases, several ongoing studies are investigating the role of TNF
inhibitors in the treatment of cancer and other inflammatory conditions.
Some of the key players
in the TNF inhibitor space are involved in strategic initiatives, such as
mergers and acquisitions and joint ventures for the co-development of products.
In addition, patent infringement issues between the manufacturers makes the
market dynamics intensely competitive. For instance, AbbVie resolved an issue
with Boehringer Ingelheim, regarding Humira’s intellectual property (IP)
rights. As per the terms of the agreement, Boehringer Ingelheim received a
non-exclusive license to Humira’s IP in the U.S.- scheduled to begin in July
2023.
Browse full research report on Tumor Necrosis Factor Inhibitor Drugs Market: https://www.grandviewresearch.com/industry-analysis/tumor-necrosis-factor-tnf-inhibitor-drugs-market
Further key findings from the study
suggest:
- Humira accounted for nearly half the
revenue share of TNF inhibitor drugs market in 2018
- Emergence of biosimilars is
anticipated to be the major growth rendering driver for the market
- Psoriasis is projected to be the most
rapidly growing application segment over the forecast period
- Increased adoption of e-commerce is a
key driver for online pharmacies
- TNF inhibitors faces an external
threat from IL-inhibitors
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/tumor-necrosis-factor-tnf-inhibitor-drugs-market/request/rs1
Grand View Research has segmented the global tumor
necrosis factor inhibitor drugs market on the basis of product, application,
sales channel, and region:
TNF Inhibitor Drugs Product Outlook
(Revenue, USD Million, 2014 - 2026)
- Humira
- Enbrel
- Remicade
- Simponi/Simponi
Aria
- Cimzia
- Biosimilars
TNF Inhibitor Drugs Application Outlook
(Revenue, USD Million, 2014 - 2026)
- Rheumatoid
Arthritis
- Psoriasis
- Psoriatic
Arthritis
- Crohn’s
Disease
- Ulcerative
Colitis
- Ankylosing
Spondylitis
- Juvenile
Idiopathic Arthritis
- Hidradenitis
Suppurativa
- Others
TNF Inhibitor Drugs Sales Channel Outlook
(Revenue, USD Million, 2014 - 2026)
- Hospital
Pharmacies
- Specialty
Pharmacies
- Online
Pharmacies
TNF Inhibitor Drugs Regional Outlook
(Revenue, USD Million, 2014 - 2026)
- North
America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Spain
- France
- Italy
- Asia
Pacific
- Japan
- China
- India
- South
Korea
- Australia
- Latin
America
- Brazil
- Mexico
- Argentina
- MEA
- South
Africa
- Saudi
Arabia
- UAE
About
Grand View Research
Grand View Research, Inc.
is a U.S. based market research and consulting company, registered in the State
of California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For
more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment